Transfusion dependence, very high-risk cytogenetics, and high serum ferritin were identified as risk factors for death in a multivariable analysis.
Though fludarabine and melphalan led to increased treatment-related mortality, the combination also led to decreased relapse incidence compared with fludarabine and busulfan.
Researchers sought to determine if nonmyeloablative HSCT conditioning was noninferior to myeloablative approaches in more vulnerable patients with AML.
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
A systematic literature review showed that erythropoietin-stimulating agents positively influenced outcomes of patients with MDS-associated anemia.
Results of a study on the influence of induction chemotherapy on transplant outcomes for patients with acute myeloid leukemia.
Researchers evaluated the proportion of patients who had not experienced relapse at 6 months after initiation of azacitidine treatment.
A personalized prediction model for probability of survival in patients with MDS who undergo HCT is presented at the ASH 2018 Annual Meeting.
Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
